//

Entremed, Inc.

Posted Mon, 09/14/2009 - 12:34 by Zefu

Entremed, Inc.

9640 Medical Center Drive, Suite 200
Rockville, MD 20850
USA
Phone: (301) 217-9858
Fax: (301) 217-9594
Email: christopherc@entremed.com
Web Site: http://www.entremed.com/

A. Company Profile

EntreMed (NASDAQ:ENMD) is a biopharmaceutical company developing angiogenesis therapeutics that inhibits abnormal blood vessel growth associated with a broad range of diseases such as cancer.

B. Products

Product Pipelines
Product Indication Clinical Status
Angiostatin Various tumors Phase I
Endostatin Various tumors Phase I
MKC-1 Ovarian and endometrial cancers Phase II
Panzem Breast cancer, prostate cancer, and multiple myeloma Phase II

1. Angiostatin

Angiostatin is a recombinant version of a naturally occurring angiogenesis inhibitor and a component of plasminogen, a protein known to be involved in coagulation.

2. Endostatin

Endostatin is a recombinant version of a naturally occurring protein. It targets abnormal blood vessel growth associated with a broad range of diseases including cancer.

3. Panzem

Panzem (2-methoxyestradiol) disrupts microtubules, the scaffold of cells that actively participates in cell division, leading to the down regulation of HIF (hypoxia inducible factor 1 alpha). It targets rapidly growing cells with relatively high specificity and does not kill healthy cells.